DGAP-News

HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery

DGAP-News: HeartBeat.bio AG / Key word(s): Alliance HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery 12.09.2022 / 10:00 CET/CEST The issuer is solely responsible for the content of this announcement. HeartBeat.bio and Molecular Devices announce collaboration to automate and scale cardiac organoids for high-throughput screening in drug discovery

VIENNA and SAN JOSE, CA – Sept. 12 – HeartBeat.bio AG, a biotech company developing cardiac organoids (Cardioids) for drug discovery, and Molecular Devices, LLC., a leading provider of high-performance life science solutions, have entered into a co-development agreement. With cardiovascular diseases the leading cause of death worldwide – claiming 34 lives every minute – and cardiotoxicity a leading cause of drug withdrawals, this collaboration will provide automated solutions to better model disease physiology, discover novel drug targets, and test cardiac toxicity using 3D cell cultures that more accurately represent human biology as compared to traditional animal models. The commercialized offering will enable researchers to reliably scale production of Cardioids and advance cardiac drug discovery, and will be compatible with Molecular Devices’ Organoid Innovation Center solutions available today.

“The combination of HeartBeat.bio’s proprietary Cardioid technology and Molecular Devices’ automated 3D cell culture and image analysis solutions, defines a powerful and compelling partnership. Together, we are committed to develop and commercialize the world’s first integrated, end-to-end high-throughput human cardiac organoid screening platform,” said Michael Krebs, CEO of HeartBeat.bio. “The collaboration establishes the foundation for HeartBeat.bio’s strategy to apply this unique 3D biology platform for cardiac drug development partnerships with pharma and proprietary discovery programs in heart failure.”